



Ifw 1 mo 8

PATENT
Customer No. 22,852
Attorney Docket No. 09605.0017

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Bernat VIDAL JUAN et al.

Application No.: 10/574,101

Filed: March 31, 2006

For: **PYRIMIDIN-2-AMINE
DERIVATIVES AND THEIR USE
AS A2B ADENOSINE RECEPTOR
ANTAGONISTS**

) Group Art Unit: *Not Yet Assigned*

) Examiner: *Not Yet Assigned*

) Confirmation No.: *Not Yet Assigned*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents on the attached listing. This Supplemental Information Disclosure Statement is being filed within three months of the date of entry of the national stage in an international application.

A copy of the U.S. patent is not attached. Copies of the listed foreign and non-patent literature documents are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /VB/


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: 
Carlos M. Tellez
Reg. No. 48,638

Dated: July 11, 2006



IDS Form PTO/SB/08: Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/574,101
				Filing Date	March 31, 2006
				First Named Inventor	Bernat VIDAL JUAN
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	09605.0017

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US-5,763,448	09 JUN 1998	Carling et al.	
	2	US-2005/0004149	06 JAN 2005	Harada et al.	
		US-			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	3	WO 97/33883	18 SEP 1997			
	4	WO 98/24782	11 JUN 1998			
	5	WO 99/65897	23 DEC 1999			
	6	WO 01/62233 A2	30 AUG 2001			
	7	WO 02/20495 A2	14 MAR 2002			
	8	WO 02/22608 A1	21 MAR 2002			
	9	WO 02/24893 A2	28 MAR 2002			
	10	WO 2005/033085 A1	14 APR 2005			
	11	EP 1 439 175 A1	21 JUL 2004			
	12	CA 2 463 284	01 MAY 2003			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
	13	Bondavalli, Francesco et al., "3-5-diphenyl-1H-pyrazole derivatives IX. 2-substituted 4-phenyl-5-(3,5-diphenyl-1H-pyrazol-1-yl) pyrimidines with platelet antiaggregating and other activities," <i>Il Farmaco</i> , 47(2):171-190 (1992).	
	14	Fischer, Gerhard W., et al., "Tetrazole compounds. 8[1]. Synthesis of tetrazolylpyrimidines from tetrazolyl-substituted enamino ketones," <i>J. Heterocyclic Chem.</i> , 30:1517-1519 (1993).	
	15	Palanki, Moorthy S.S., et al., "Structure-activity relationship studies of ethyl 2-[(3-methyl-2,5-dioxo(3-pyrrolinyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate: An inhibitor of AP-1 and Kf-kB Mediated Gene Expression," <i>Bioorganic & Medicinal Chemistry Letters</i> , 12:2573-2577 (2002).	
	16	English-language abstract for WO 03/035639, dated May 1, 2003. U.S. Publication No. 2005/0004149 is a member of the patent family of WO 03/035639.	
Examiner Signature	/Venkataraman Balasubramanian/		Date Considered 09/29/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /VB/